Auriga Upgrades Omnicell to Buy (OMCL)

Auriga analyst Gene Mannheimer upgraded Omnicell OMCL to Buy. Omnicell is a company specializing in medication and supply dispensing systems for the healthcare industry. According to Auriga, "We believe the company won a new Supply contract at Scott & White Hospital: Though yet unannounced, our sources suggest that OMCL won a highly competitive deal at Scott & White, a 636-bed hospital in Texas for its Supply line of cabinets." OMCL was upgraded to Buy with a price target of $15. OMCL is currently trading at $11.84. Mannheimer concluded, "We find valuation compelling at these levels and view the risk/reward as favorable - $1 downside and $3+ upside."